At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 13 enrolled
Drug / intervention
rMenB+OMV NZbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
In Brief
A Phase 3 clinical trial evaluating rMenB+OMV NZ for Prevention of the Meningococcal Disease. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The study will evaluate the immunogenicity and safety of the rMenB+OMV NZ in an adult population potentially at risk for meningococcal disease (e.g. lab workers).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrevention of the Meningococcal Disease
CountriesGermany
CollaboratorsGlaxoSmithKline
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartAug 2013
Primary CompletionApr 2014
TodayJul 2026
First PostedJul 30, 2013
Enrollment StartAug 1, 2013
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.9 years ago
Interventions
rMenB+OMV NZbiological
Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain